English
Нефропротективное значение N-ацетилцистеина для пациентов с сочетанной травмой, а также другие аспекты применения в клинической практике данного вещества
DOI: https://dx.doi.org/10.18565/urology.2024.1.129-134
Мизиев И.А., Махов М.Х., Махова А.Б., Ширитова Л.А., Губжокова Л.Б.
1) ФГБОУ ВО «Кабардино-Балкарский государственный университет им. Х. М. Бербекова», Нальчик, Россия; 2) ФГАОУ ВО «Российский национальный исследовательский медицинский университет имени Н.И. Пирогова» Министерства здравоохранения РФ, Москва, Россия
Литература
1. Miziev I.A., Makhov M.Kh. Investigation of serum cysteine concentration to monitor glomerular filtration rate for early diagnosis of acute kidney injury in patients with combined trauma. Urologiia. 2017;5:48–51. DOI: https://dx.doi.org/10.18565/urology.2017.5.48–51. Russian (Мизиев И.А., Махов М.Х. Исследование сывороточной концентрации цистатина С для мониторинга скорости клубочковой фильтрации с целью ранней диагностики острого повреждения почек у больных с сочетанной травмой. Урология. 2017;5:48–51. DOI: https://dx.doi.org/10.18565/urology.2017.5.48–51). 2. Miziev I.A., Makhov M.H. Diagnosis of acute kidney injury in the early stages of treatment of victims of combined trauma using a high-precision biomarker cystatin S. Materials of the VII All-Russian Conference of students, postgraduates and young scientists «Promising innovative projects of young scientists». Nalchik 2017. Р. 171–174. Russian (Мизиев И.А., Махов М.Х. Диагностика острого повреждения почек на ранних этапах лечения пострадавших от сочетанной травмы с помощью высокоточного биомаркера цистатина С. Материалы VII Всероссийской конференции студентов, аспирантов и молодых ученых «Перспективные инновационные проекты молодых ученых». Нальчик, 2017. С. 171–174). 3. Miziev I.A., Makhov M.H. Cystatin C in the early diagnosis of acute renal failure in patients with concomitant trauma. Bulletin of the Russian Academy of Natural Sciences. 2018 г. Р. 51–55. Russian (Мизиев И.А., Махов М.Х. Цистатин С в ранней диагностике острой почечной недостаточности у больных с сочетанной травмой. Вестник Российской академии естественных наук. 2018. С. 51–55). 4. Nita M., Grzybowski A. The Role of the Reactive Oxygen Species and Oxidative Stress in the Pathomechanism of the Age-Related Ocular Diseases and Other Pathologies of the Anterior and Posterior Eye Segments in Adults. Oxid Med Cell Longev. 2016;2016:3164734. DOI: 10.1155/2016/3164734. 5. Ung L. et al. Oxidative stress and reactive oxygen species: a review of their role in ocular disease. Clinical Sci. 2017;131(4):2865–2883. DOI: 10.1042/CS20171246. 6. Yadav U.C., Kalariya N.M., Ramana K.V. Emerging role of antioxidants in the protection of uveitis complications. Curr Med Chem. 2011;18(6):931–942. DOI: 10.2174/092986711794927694. 7. Kumar N. Rajendran et al. The Influence of Light on Reactive Oxygen Species and NF-кB in Disease Progression. Antioxidants (Basel). 2019;8(640):1–16. DOI: 10.3390/antiox8120640. 8. Chatterjee S. Oxidative Stress, Inflammation, and Disease. Oxidative stress and biomaterials / ed.: T. Dziubla, D. A. Butterfield. London, 2016. Ch. 2. P. 35–58. DOI: 10.1016/b978-0-12-803269-5.00002-4. 9. Pavarino E.C. et al. Glutathione: Biosynthesis and Mechanism of Action. Glutathione. Biochemistry, mechanisms of action and biotechnological implications / ed.: N. Labrou, E. Flemetakis. New-York, 2013. Ch. 1. P. 1–34. 10. Zenkov N.K., Kolpakov A.R., Menshchikova E.B. The redox-sensitive Keap1/Nrf2/ARE system as a pharmacological target in cardiovascular pathology. Siberian Scientific Medical Journal. 2015;35(5):5–25. Russian (Зенков Н.К., Колпаков А.Р., Меньщикова Е.Б. Редокс-чувствительная система Keap1/Nrf2/ARE как фармакологическая мишень при сердечно-сосудистой патологии. Сибирский научный медицинский журнал. 2015;35(5):5–25). 11. Bachhawat A.K., Yadav S. The glutathione cycle: Glutathione metabolism beyond the γ-glutamyl cycle. IUBMB Life. 2018;70(7):585–592. DOI: 10.1002/iub.1756. 12. Rushworth G.F., Megson I.L. Existing and potential therapeutic uses for N-acetylcysteine: the need for conversion to intracellular glutathione for antioxidant benefits. Pharmacol Ther. 2014;141(2):150–159. DOI: 10.1016/j.pharmthera.2013.09.006. 13. Samuni Y. et al. The chemistry and biological activities of N-acetylcysteine. Biochim Biophys Acta. 2013;1830(8):4117–4129. DOI: 10.1016/j. bbagen.2013.04.016. 14. Atkuri K.R. et al. N-Acetylcysteine – a safe antidote for cysteine/glutathione deficiency. Curr Opin Pharmacol. 2007;7(4):355–339. DOI: 10.1016/j.coph.2007.04.005. 15. Wu F. et al. Glutathione metabolism and its implications for health. J. Nutr. 2004;134(4):489–492. DOI: 10.1093/jn/134.3.489. 16. Cacciatore I. et al. Prodrug approach for increasing cellular glutathione levels. Molecules. 2010;15(3):1242–1264. DOI: 10.3390/molecules15031242. 17. Raghu G. et al. The Multifaceted Therapeutic Role of N-Acetylcysteine (NAC) in Disorders Characterized by Oxidative Stress. Curr Neuropharmacol. 2021;19(8):1202–1224. DOI: 10.2174/1570159x19 666201230144109. 18. Tenório M.C.D.S. et al. N-Acetylcysteine (NAC): Impacts on Human Health. Antioxidants (Basel). 2021;10(6):967. doi: 10.3390/antiox10060967. 19. Radtke K.K. et al. Interaction of N-acetylcysteine and cysteine in human plasma. J Pharm Sci. 2012;101(12):4653–4659. DOI: 10.1002/jps.23325. 20. Zhou J. et al Intravenous Administration of Stable-Labeled N-Acetylcysteine Demonstrates an Indirect Mechanism for Boosting Glutathione and Improving Redox Status. J Pharm Sci. 2015;104(8):2619–2626. DOI: 10.1002/jps.24482. 21. Shi Z., Puyo C.A. N-Acetylcysteine to Combat COVID-19: An Evidence Review. Ther Clin Risk Manag. 2020;16:1047–1055. DOI: 10.2147/ TCRM.S273700. 22. Машковский М.Д. Лекарственные средства. 16-е изд. Москва: Новая волна, 2020. 1216 с. 23. Akca T. et al. The effect of N-acetylcysteine on pulmonary lipid peroxidation and tissue damage. J Surg Res. 2005;129(1):38–45. DOI: 10.1016/j. jss.2005.05.026. 24. Aldini G. et al. N-Acetylcysteine as an antioxidant and disulphide breaking agent: the reasons why. Free Radic Res. 2018;52(7):751–762. DOI: 10.1080/10715762.2018.1468564. 25. Jiao Y. et al. N-acetyl cysteine depletes reactive oxygen species and prevents dental monomer-induced intrinsic mitochondrial apoptosis in vitro in human dental pulp cells. PLoS One. 2011;11(1):Art.e0147858. DOI: 10.1371/journal.pone.0147858. 26. Szeto H.H. Mitochondria-targeted peptide antioxidants: novel neuroprotective agents. AAPS J. 2006;8(3):E521–E531. DOI: 10.1208/ aapsj080362. 27. Go Y.M., Chandler J.D., Jones D.P. The cysteine proteome. Free Radic. Biol. Med. 2015;84:227–245. DOI: 10.1016/j.freeradbiomed.2015.03.022. 28. Wardyn J.D., Ponsford A.H., Sanderson C.M. Dissecting molecular cross-talk between Nrf2 and NF-κB response pathways. Biochem Soc Trans. 2015;43(4):621–626. DOI: 10.1042/BST20150014. 29. Fratta Pasini A.M. et al. Potential Role of Antioxidant and Anti-Inflammatory Therapies to Prevent Severe SARS-Cov-2 Complications. Antioxidants (Basel). 2021;10(2):Art.272. DOI: 10.3390/antiox10020272. 30. Saddadi F. et al. The effect of treatment with N-acetylcysteine on the serum levels of C-reactive protein and interleukin-6 in patients on hemodialysis. Saudi J Kidney Dis Transpl. 2014;25(1):66–72. DOI: 10.4103/1319-2442.124489. 31. Ibrahim H. et al. Therapeutic blockade of inflammation in severe COVID-19 infection with intravenous N-acetylcysteine. Clin Immunol. 2020;219:Art. 108544. DOI: 10.1016/j.clim.2020.108544. 32. AlMatar M., Batool T., Makky E.A. Therapeutic Potential of N-Acetylcysteine for Wound Healing, Acute Bronchiolitis, and Congenital Heart Defects. Curr Drug Metab. 2016;17(2):156–67. DOI:10.2174/1389200217666151210124713 33. Pei Y. et al. Biological Activities and Potential Oral Applications of N-Acetylcysteine: Progress and Prospects. Oxid Med Cell Longev. 2018;2018:Art. 2835787. DOI: 10.1155/2018/2835787. 34. Nascimento M.M. et al. Effect of oral N-acetylcysteine treatment on plasma inflammatory and oxidative stress markers in peritoneal dialysis patients: a placebo-controlled study. Perit Dial Int. 2010;30(3):336–342. DOI: 10.3747/pdi.2009.00073. 35. Decramer M., Rutten-van Mzlken M., Dekhuijzen P.N.R. et al. Effects of N-acetylcysteine on outcomes in chronic obstructive pulmonary disease (Bronchitis Randomized on NAC Cost-Utility Study, BRONCUS): a randomized placebo-controlled Trial. Lancet. 2005;365:1552–1560. 36. Demedts M., Behr J. et al. High-dose acetylcysteine in idiopathic pulmonary fibrosis. N. Eng. J. Med. 2005;353:2229–2242. 37. Feldman L., Efrati S. et al. Gentamicin-induced ototoxicity in hemodialysis patients is ameliorated by N-acetylcysteine. Kidney Int. 2007;72(3):359–363. DOI: 10.1038/sj.ki.5002295. 38. Fiorentini С., Falzano L., Rivabene R., Fabbri A., Malorni W. N-acetylcysteine protects epithelial cells against the oxidative imbalance due со Clostridium difficile toxins. FEBS Lett. 1999;453(1–2):124–128. 39. Grandijean E.M., Berthet P. et al. Efficasy of oral long-term N-acetylcysteine in chronic bronchopulmonary disease: a meta-analysis of published duble-blind, placebo controlled clinical trials. Clin. Ther. 2000;22:209–221. 40. Regueira F.M. et al. Ischemic damage prevention by Acetylcysteine treatment of the donor before orthotopic liver transplant. Transplantation Proceedings. 1997;29:3347–3349. 41. Stey C. et al. The effect of oral N-acetylcysteine in chronic bronchitis: a quantitative systematic review // Eur. Respir. J. 2000;16:253. 42. Van Zandwijk N., Dalesio О., Pastorino U. et al. EUROSCAN, a randomized trial of vitamin A and N-acetylcysteine in patients with head and neck cancer or lung cancer. J. Natl. Cancer Inst. 2000;92:977–986. 43. Zheng С.Н., Ahmed К., Rikicomi N., Marrinez G., Nagaiake T. The effects of S-carboxymethylcysteine and N-acetylcysteine on the adherence of Moraxella catarrhalis to human pharyngeal epithelial cells. Microbiol. Immunol. 1999;43(2):107–113. 44. Павлов В.Н., Пушкарев А.М., Кондратенко Я.В., Сафиуллин Р.И., Алексеев А.В.. Маркеры повреждения почек и нефропротективная терапия при радикальной цистэктомии. Урология. 2015;5:27–30. 45. Schwalfenberg, G.K. N-Acetylcysteine: A Review of Clinical Usefulness (an Old Drug with New Tricks). J Nutr Metab. 2021;2021:Art. 9949453. DOI: 10.1155/2021/9949453.
Об авторах / Для корреспонденции
А в т о р д л я с в я з и: М. Х. Махов – к.м.н., доцент кафедры факультетской и эндоскопической хирургии КБГУ им. Х. М. Бербекова, Нальчик, Россия; e-mail: mahov_murat@mail.ru
Похожие статьи
